PreforPro.
A bacteriophage-based prebiotic that clears out bad gut bacteria to make room for the good ones. Uses bacteriophages to selectively kill harmful gut bacteria, making room for beneficial strains to thrive.
Reviewed March 2026
- Category
- Compound
- Also filed under
- Supports beneficial gut bacteria growthTargets harmful bacteria selectivelyWorks within hours, not weeks
What PreforPro is, and what it does.
- Does it work
- Novel science with a few small human trials showing real microbiome shifts. Interesting, but still early. Best paired with probiotics.
- How much to take
- 15 mg per day. That's the standard dose across all the published studies. Simple.
- Time to feel it
- Two to four weeks for digestive comfort. Stool testing picks up the shift in which bacteria dominate well before you would notice anything.
- The first dose
- Nothing dramatic. The phages act in the gut lumen from the same day, and the change registers in the microbiome long before it registers as comfort.
- With regular use
- By week 3-4, paired with probiotics, you may notice improved digestion and regularity. The microbiome shifts are measurable in stool tests.
- How well tolerated
- Well tolerated. Bacteriophages are incredibly specific to their bacterial targets and don't affect human cells at all. They're already in your gut naturally by the trillions.
- How it feels
- You won't feel the phages working. What you might feel is the downstream effect: less gas, less bloating, smoother digestion. Subtle but real.
- The overlooked benefit
- It carries no fermentable carbohydrate, so it works as a prebiotic without the gas load a fibre one can bring. Useful if fibre prebiotics have not sat well with you.
15mg a day is where PreforPro works.
Source: Gruenwald et al., 2020; Gindin et al., 2019
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Increases beneficial bacteria within hours
- Works as a prebiotic without fiber
- Enhances probiotic effectiveness
Questions people ask about PreforPro.
- Do I need to take this with a probiotic?
- You don't have to, but you should. PreforPro clears space for good bacteria. Taking a probiotic at the same time fills that space with the strains you want.
- Can phages hurt my good bacteria?
- No. These phages are extremely specific. They only target certain harmful strains. Your Lactobacillus and Bifidobacterium are well tolerated.
- Is this the same as an antibiotic?
- No. Antibiotics kill bacteria broadly (good and bad). Phages are like snipers. They only hit their specific targets.
- How is this different from fiber prebiotics?
- Fiber feeds bacteria. PreforPro kills specific bad bacteria. Completely different mechanism, and they work well together.
- Will I feel anything?
- Probably not directly. The benefits are in your gut ecosystem, not something you'd consciously notice without testing.
- Is this safe long-term?
- Yes. Phages are a natural part of your gut ecosystem. You already have trillions of them.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
The bacteriophage blend targets specific Escherichia coli strains and releases the nutrients those cells held, which nearby organisms can then use. Spore-forming Bacillus survives gastric transit and is the usual partner in these formulas.
Bacillus coagulans is the strain most often formulated alongside the phage blend, since it germinates in the small intestine where the phage has cleared competing coliforms. The pairing is a formulation convention with a stated mechanism.
The phages act only on target Escherichia coli and leave lactobacilli untouched, so lysing competitors frees nutrients and surface for the added strains. The mechanism is stated and the human evidence base is still thin.
Bacteriophages are strain-specific and do not lyse lactic acid bacteria, so they reduce a competing population without touching the added one. That is the rationale for combining them in one capsule.
The phages in this class are selected against Escherichia coli hosts, and phage host range is narrow: a coliphage does not infect a lactobacillus. That specificity is the reason a phage preparation can sit in the same capsule as a live lactic acid bacterium without lysing it. Compatibility is well grounded. A joint effect on any endpoint is not.
Bifidobacteria are outside the host range of E. coli-targeting phages, so the two components coexist in a blend. The proposed sequence is that lysing target bacteria releases nutrients and frees niche space that other residents can use. That second step is a hypothesis, not a measurement.
As with other bifidobacteria, a coliphage preparation leaves this species untouched, which is why the two are formulated together. The pairing is a compatibility statement. Nothing here shows the combination outperforms either component.
Bacteriophages infect bacteria only. A yeast has neither the surface receptors nor the machinery a phage needs. The two are therefore fully compatible in one product. That is settled biology and says nothing about combined benefit.
Inulin feeds resident bacteria by supplying fermentable carbohydrate, a completely different route from selectively lysing a target population. Combining a fermentable fibre with a phage preparation covers two independent levers on community composition. Composition is a marker, and the combination has not been measured here.
FOS is fermented by lactobacilli and bifidobacteria and does not interact chemically with phage particles. Formulators pair the two so that a fibre-based and a non-fibre approach sit in the same dose. The rationale is mechanistic rather than trial-based.
Resistant starch feeds primary degraders and, through cross-feeding, butyrate producers. A phage preparation acts on a different axis, by reducing a specific bacterial population rather than feeding one. Pairing them combines subtraction with addition.
Butyrate is the preferred fuel of colonocytes and is the downstream product a fermentation-based approach aims at. Supplying it directly reaches the same endpoint without depending on the resident community. The two approaches converge on the same tissue by different routes.
Activated charcoal adsorbs proteins and viral particles non-selectively, and a phage is a protein-coated particle. Taken together, a share of the phage dose is likely bound and inactive. Separating the doses in time is the ordinary handling of an adsorbent.
Clay minerals bind viral particles onto charged surfaces, a property used deliberately in water treatment work. In the gut lumen the same binding removes phage from circulation in the community. Spacing doses is the practical response.
Carvacrol and thymol suppress gram-negative bacteria broadly, including the E. coli populations a coliphage needs as hosts. Removing the host removes the substrate on which phage replication depends. The two approaches to the same population can work against each other rather than together.
Berberine has direct antibacterial activity against gram-negative organisms and shifts community composition on its own. Suppressing the host population limits the phage amplification step, since phage numbers only rise where susceptible hosts are present. Named as competitive so the interaction is visible rather than assumed neutral.
Allicin acts against a wide bacterial range including coliforms. The same host-depletion logic applies as with other antibacterials. This is a mechanistic caution at low confidence, not a documented interaction.
Talk to a doctor before taking PreforPro if any of these apply to you: Limited human trial data, Relatively new ingredient. These are flags to check first, not effects PreforPro is known to cause.
Not medical advice. Show the label to your pharmacist.What PreforPro actually does.
Bacteriophages are viruses that only infect bacteria: each one attaches to a specific bacterial surface, injects its genes, copies itself inside, and bursts the cell, and each phage targets only certain strains.
A phage has no way to attach to or copy itself in human cells, so it passes through the gut acting only on the bacteria it can infect.
Phages only multiply where their target bacteria live, so the dose you swallow isn't the dose that acts: it amplifies where the target is abundant and does nothing where the target is absent.
Bacteria can become resistant to any single phage, which is why these preparations blend several phages that grab different surface receptors rather than relying on one.
Where PreforPro comes from.
Each virus is grown inside a batch of the bacteria it targets, which burst and release many more copies. The liquid is filtered to strip out bacterial debris, cleaned further, counted by how many bacterial colonies each sample can clear, then freeze-dried into a stable powder.
Produced by a cultured organism rather than harvested. The strain is selected and the conditions are controlled, so batches sit closer together than a field crop.
Individual lytic bacteriophages are isolated from environmental sources such as water or soil and screened for host range, then paired with a defined laboratory host strain of Escherichia coli on which they will be grown.
The host bacterium is grown in fermentation, then infected with the phage. Each infected cell releases many new particles as it lyses, which is how phage titre is built. There is no chemical synthesis step: the bacterium does the manufacturing.
The lysed culture is centrifuged and filtered to remove bacterial debris and whole cells, leaving a phage-containing filtrate.
The filtrate is further purified, typically by tangential-flow filtration and washing steps, to reduce host protein and endotoxin content, then tested against release limits.
Activity is measured as plaque-forming units on the named host strain, which is the only meaningful potency unit for this class of ingredient, and the blend is adjusted to a declared count per serving.
The standardised blend is mixed with cryoprotectants and lyophilised into a dry powder, then diluted with a carrier and filled into capsules or sachets.
The identity of the individual phages, the host strain they were grown on, the plaque-forming unit count per serving and the endotoxin release limit are usually not on a finished label.
The forms it comes in.
The essence, in one line each.
- In healthy adults, adding supplemental bacteriophages alongside Bifidobacterium animalis subsp. lactis BL04 changed the gut and blood measures the trial tracked compared with the probiotic alone.Randomised trial. Grubb et al., 2020 (Nutrients). PMID 32824480 ↗
- In healthy adults, Bacillus subtilis DE111 supplementation was reported to affect blood lipid measures and endothelial function markers. Both are laboratory and physiological markers rather than clinical outcomes.Randomised trial. Trotter RE et al., 2020 (Beneficial Microbes). PMID 33161737 ↗
These are the studies our verdict leans on, chosen from the 8 we read for PreforPro. The full linked list is below.
The studies, linked.
4 sources behind our PreforPro verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialPHAGE 3: Determination of Phage and Probiotic Synergistic Effects on Gastrointestinal HealthClinicalTrials.gov ↗120 participants, Completed
- ClinicalTrials.gov ↗
- ClinicalTrials.gov ↗
- Clinical trialEffect of PreforPro® (Prebiotic and Bacteriophage) on Urinary and Vaginal HealthClinicalTrials.gov ↗Phase 3, 50 participants, Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
